Open access · CC-BY
via OpenAlex
A role for metformin in the treatment of Dupuytren disease?
Alberto Baeri, Michaël Levraut, Serena Diazzi, Olivier Camuzard, Marianne Cegarra-Escolano, Marie-Anne Ploumellec, Thierry Balaguer, Julien Fassy, Roger Rezzonico, Savério Bellusci, Bernard P. Mari, Georges Vassaux
Biomedicine & Pharmacotherapy · 2022 · ▲ 1 citations
Abstract
Dupuytren disease (DD) is a hand-localized fibrotic disorder characterized by a scar-like, collagen-rich cord. Treatment usually comprises surgical removal of the cord, but is associated with a high relapse rate, in some cases requiring finger amputation. There is currently no consensual medical approach for treating DD. Numerous preclinical studies have highlighted antifibrotic properties of metformin, and the aim of this study was to assess a potential antifibrotic role of metformin in DD. Fibroblasts from DD cords (DF) and phenotypically normal palmar fascia (PF) were extracted from surgical specimens and cultured. The fibrotic status of DF and PF was compared at baseline, and under profibrotic (TGF-β stimulation) and antifibrotic (metformin stimulation) conditions, using quantitative RT-PCR, western blot, immunocytochemistry, and a functional fibroblast contraction assay. At baseline, DF showed higher levels of fibrotic markers and contraction capacity compared with PF. Both types of fibroblasts responded to TGF-β stimulation. Treatment of DF and PF with metformin did not affect basal levels of fibrotic markers and contraction but largely prevented their induction by TGF-β. In conclusion, our data show that metformin inhibits TGF-β-induced expression of fibrotic markers and contraction in hand-derived fibroblasts. This supports the case for a clinical trial to assess the repurposing of metformin as an adjuvant to surgery, to prevent, reduce, or delay recurrence in at-risk DD patients.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.biopha.2022.112930
- Canonical
- link ↗
- Fetched
- 2026-10-08 MST
Cite this
APA
Baeri, A., Levraut, M., Diazzi, S., Camuzard, O., Cegarra-Escolano, M., Ploumellec, M., Balaguer, T., Fassy, J., Rezzonico, R., Bellusci, S., Mari, B.P., & Vassaux, G. (2022). A role for metformin in the treatment of Dupuytren disease?. <em>Biomedicine & Pharmacotherapy</em>. https://doi.org/10.1016/j.biopha.2022.112930
Vancouver
Baeri A, Levraut M, Diazzi S, Camuzard O, Cegarra-Escolano M, Ploumellec M, et al. A role for metformin in the treatment of Dupuytren disease?. Biomedicine & Pharmacotherapy. 2022. doi:10.1016/j.biopha.2022.112930.
BibTeX
@article{alberto2022Arolef,
title = {A role for metformin in the treatment of Dupuytren disease?},
author = {Alberto Baeri and Michaël Levraut and Serena Diazzi and Olivier Camuzard and Marianne Cegarra-Escolano and Marie-Anne Ploumellec and Thierry Balaguer and Julien Fassy and Roger Rezzonico and Savério Bellusci and Bernard P. Mari and Georges Vassaux},
journal = {Biomedicine & Pharmacotherapy},
year = {2022},
doi = {10.1016/j.biopha.2022.112930},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Age and Ageing 2021
Open access · CC-BY
Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-centre study
Tungs' Taichung Metroharbour Hospital 2019
Open access · US-GOV
Association of Uremic Sarcopenia and Mitochondrial Copy Number and Its Clinical Correlates in Taiwanese Hemodialysis Patients
University of Oklahoma 2025
Open access · US-GOV
A Preliminary Elucidation of the Role of Dietary Fiber in Mitigating Sarcopenia Risk in Head and Neck Cancer
Cell 2025
Citation only
Prevalent mesenchymal drift in aging and disease is reversed by partial reprogramming.
The Ukrainian Biochemical Journal 2018
Open access · CC-BY
Effects of alpha-ketoglutarate on lifespan and functional aging of Drosophila melanogaster flies
Bone 2027
Citation only